Advanced Oncotherapy (AVO)

 

AVO Share PerformanceMore

52 week high209.88 27/05/16
52 week low47.00 16/12/16
52 week change -111.00 (-63.43%)
4 week volume2,061,085 27/01/17

Media for (AVO)

Presenter: Donatella Ungaro
15/12/2016
Presenter: Nicolas Serandour
12/10/2016

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Financing agreement

RNS Number: 4882X Advanced Oncotherapy PLC 22 February 2017 ADVANCED ONCOTHERAPY PLC ("Advanced Oncotherapy" or the "Company") Financing agreement Advanced Oncotherapy plc (AIM: AVO), the developer of next generation proton therapy systems for cancer treatment, announces it has secured a flexible and staged 26 million financing ag...

Investor presentation

RNS Number: 0004X Advanced Oncotherapy PLC 16 February 2017 ADVANCED ONCOTHERAPY PLC ("Advanced Oncotherapy" or the "Company") Investor presentation Advanced Oncotherapy (AIM: AVO), the developer of next generation proton therapy systems for cancer treatment, announces that it will be hosting investor and analyst presentations in Lond...

Advanced Oncotherapy strengthens its board

Advanced Oncotherapy has appointed Dr Nick Plowman as a non-executive director with immediate effect. Plowman is se...

Directorate Change

RNS Number: 3932W Advanced Oncotherapy PLC 09 February 2017 ADVANCED ONCOTHERAPY PLC ("Advanced Oncotherapy" or the "Company") Directorate Change Appointment of Dr Nick Plowman as Non-Executive Director Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces t...

Significant shareholder

RNS Number: 2835W Advanced Oncotherapy PLC 08 February 2017 8 February 2017 ADVANCED ONCOTHERAPY PLC ("Advanced Oncotherapy" or the "Company") Significant Shareholder Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it was informed on 7 February 2017 th...

Sinophi update

RNS Number: 0521W Advanced Oncotherapy PLC 06 February 2017 ADVANCED ONCOTHERAPY PLC ("Advanced Oncotherapy" or the "Company") Sinophi update Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has come to an agreement with Sinophi Healthcare Limited ("...

Directorate Changes

RNS Number: 1494V Advanced Oncotherapy PLC 26 January 2017 Advanced Oncotherapy plc (" Advanced Oncotherapy " or the "Company") Directorate Changes Appointment of Non-Executive Directors Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces the appointment of Professor Ste...

Advanced Oncotherapy says Sinophi wants to terminate orders

Proton therapy systems developer Advanced Oncotherapy was informed by Sinophi Healthcare that it wanted to terminat...

Fundamental DataMore

EPS-0.51
Dividend yield0 %

Equity Research (AVO)

hardman & co
Advanced Oncotherapy Plc
02/11/2016
AVO is focused on delivering a more affordable, novel proton-based radiotherapy system, based on a technology originally developed and tested at the world renowned CERN. Planning Permission for its...
Advanced Oncotherapy Plc
01/11/2016
Eco Animal Health (EAH.L) 495p £317.9m The specialist in the development, registration and marketing of pharmaceutical products for animals has received a marketing authorisation from the Thailand...
hardman & co
Advanced Oncotherapy Plc
28/10/2016
AVO is focused on delivering a more affordable, novel proton-based radiotherapy system, based on a technology originally developed and tested at the world renowned CERN. Planning Permission for its...

Latest discussion posts More

  • Re: DIR. BUYS

    Priceless! Dr Plowman has been rewarded for flouting stock market rules by being appointed a as full Non-Executive Director.
    9-Feb-2017
    Kenj2
  • Re: DIR. BUYS

    Directors buys are very positive for a company, but why was this one announced a full 8 months after the event? AVO have history in this, back in November they announced ...
    8-Feb-2017
    Kenj2
  • DIR. BUYS

    Dr. N Plowman holds. 2.63m 3.6%
    8-Feb-2017
    paul1945

Users' HoldingsMore

Users who hold Advanced Oncotherapy also hold..
LLOYDS GRP.20%
SIRIUS MINERALS16%
BP13%
TAYLOR WIMPEY11%
BT GROUP10%

Codes & Symbols

ISINGB00BD6SX109
SymbolsAVO, LSE:AVO, AVO.L, AVO:LN, LON:AVO, XLON:AVO